

Editorial

One last time

Journal of Cancer Research and Therapeutics (JCRT) was started in early 2005. It was to be a platform for oncologists from India and Asia-Pacific. Science knows no boundaries. Articles from across the world poured in. The reach of JCRT became global. The journal soon got pub indexed. Citation index reached more than one. It was listed as one of the ten journals in the area of medicine (current science).

Now, it is the time for the journal which needs to create more impact on the world stage. If could start with China and Asia-Pacific, I wish to acknowledge few people in person though the credit for the success story goes to every member of the editorial board, contributors, and reviewers. Dr. Rajiv Sarin, Dr. Shyam Srivastava, Dr. Rajesh Vaishistha, Dr. Rakesh Jalali, and Chaitra Jaidev.

Journals have proliferated exponentially over the past 10–15 years. Digital journals have ensured a worldwide reach at an affordable cost. The responsibility of peer reviewers and editors, thus, is more than ever peer review has remained an honorary job. It is a herculean task for any fledgling journal to get the best referees who will review in time. The delays in turnaround time troubled us. The financial remuneration for referees was discussed with core group and the lead referees: it was felt not very prudent to lure reviewers with financial incentives. The ever-proliferating journals of all have put

a pressure on this rare species, “reviewers.” The scientific community collectively needs to deliberate on the issue of financial remuneration to referees. Plagiarism is an emerging concern for editors. The artificial intelligence-based plagiarism checks sometimes are not good enough to spot even a blatant plagiarism of ideas and data. This requires ever-vigilant referees. JCRT has had its share of this problem. Those who Plagiarized were penalized. Publishing any journal is a gargantuan exercise. It is a co-ordinated effort. JCRT has done splendidly so far.

It is now evident that important research performed and published in journals in language other than English goes unnoticed. It is indeed a colossal loss of information to the scientific community. Similarly, significant literature in English goes unnoticed in non-English-speaking countries. That is why JCRT has extended its reach to China. Abstracts are translated into Chinese to enhance and promote the ease of access of articles published in JCRT to a larger non-English-speaking audience.

JCRT is on its way to be global. I thank everyone making JCRT what it is today. A new editor, new thought, and new style will be evident with the new editor and his team. One last time, I say thank you all.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

Cite this article as: Huilgol N. One last time. J Can Res Ther 2016;12:1215.

Nagraj Huilgol

Department of
Radiation Oncology,
Nanavati Super
Speciality Hospital,
Mumbai, Maharashtra,
India

For correspondence:
Dr. Nagraj Huilgol,
Nanavati Hospital,
ACRO, Basement
Level, S. V. Road,
Vile Parle West,
Mumbai - 400 056,
Maharashtra, India.
E-mail: nagrajhuilgol@gmail.com

Access this article online

Website: www.cancerjournal.net
DOI: 10.4103/0973-1482.199543

Quick Response Code:

